SCHEMBL20464429

SCHEMBL20464429

CC(C)(C)C(=O)NCC1(O)COC1

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADA P00813 8/20 0.35
PRKCA P17252 2/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
POLB P06746 1/20 0.31
HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20462573 0.82 POLB (0.33) PRKCAPOLBHDAC6
SCHEMBL20464427 0.81 EPHX1 (0.40) PRKCAPOLBHDAC6
SCHEMBL15617682 0.78 BRD4 (0.35) POLB
SCHEMBL19123536 0.78 NPSR1 (0.35)
SCHEMBL21814069 0.75 GABRA1 (0.31)
SCHEMBL24774812 0.71 EPHX1 (0.31)
SCHEMBL24847188 0.71 ALDH1A1 (0.40)
SCHEMBL20462570 0.69 OPRM1 (0.38) PRKCAPOLBHDAC6
SCHEMBL20464446 0.68 PIK3C3 (0.33)
SCHEMBL17780234 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US disclosed
US-11220506-B2 Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors BEIGENE, LTD. (KY) 2022-01-11 US disclosed
US-20200207774-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2020-07-02 US disclosed
US-10487068-B2 Pyridazine derivatives as RORc modulators GENENTECH, INC. (US) 2019-11-26 US disclosed
WO-2019047915-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS BEIGENE, LTD. (KY) 2019-03-14 WO disclosed
US-20180222882-A1 PYRIDAZINE DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2018-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10487068-B2 Pyridazine derivatives as RORc modulators RORC, RORB, RORA ADA 2412/4885PRKCA 1699/4885ADORA2A 46/4885
US-20180222882-A1 PYRIDAZINE DERIVATIVES AS RORc MODULATORS RORC, RORB, RORA ADA 2412/4885PRKCA 1699/4885ADORA2A 46/4885
US-20200207774-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS PIK3CD, PIK3R5, PIK3CA ADA 2600/4885PRKCA 40/4885ADORA2A 1521/4885
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 ADA 4135/4885PRKCA 514/4885ADORA2A 4682/4885
US-11220506-B2 Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors PIK3CD, PIK3R5, PIK3CA ADA 2600/4885PRKCA 40/4885ADORA2A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.